Q&A: Page 2

Exclusive interviews with industry leaders


  • story image
    Image attribution tooltip
    Real Chemistry/PharmaVoice

    Lessons from improv: Shankar Narayanan's 'yes, and' approach to healthcare leadership

    Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.

    Taren Grom • April 4, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Time-saving tech lights Alcon's path into digital innovation

    Kevin Yapp, global head or omni-channel transformation at the Swiss eye health company shares why the customer should be a  North Star when developing digital tools.

    Kim Ribbink • April 4, 2022
  • story image
    Image attribution tooltip

    Sangamo Therapeutics

    Sangamo has its finger on the next evolution of gene editing

    Sangamo Therapeutics' CEO Sandy Macrae is bullish on his company’s ability to transform the genomic medicine arena.

    Taren Grom • March 31, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Rare Patient Voice's president is striving to create a five-star experience for patients

    Successful clinical trial recruitment depends on listening to and empowering patients.

    Kim Ribbink • March 23, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Why Astellas is adopting a 'focus area approach' to partnerships

    Chief Strategy Officer, Naoki Okamura, explains why new trends and innovations require a different approach to alliances.

    Kim Ribbink • March 22, 2022
  • story image
    Image attribution tooltip
    Retrieved from PharmaVOICE on March 21, 2022

    BioMarin's new global head of advocacy is tackling the holy grail of patient engagement

    In her new role, Dr. Roz is keeping her patient-first approach.

    Taren Grom • March 21, 2022
  • story image
    Image attribution tooltip

    Novartis' manufacturing facility for innovative cell and gene therapies in Stein, Switzerland. Permission granted by Novartis.

    How Novartis kept its supply chain intact during COVID-19

    In an agile pivot, Amit Nastik led Novartis’ manufacturing operations through the pandemic without losing supply chain reliability. 

    Taren Grom • March 16, 2022
  • story image
    Image attribution tooltip

    Image courtesy of Medigene.

    Medigene's CEO on striking a collaboration deal with BioNTech

    The two companies recently announced a $29 million collaboration. 

    Jared Whitlock • March 15, 2022
  • story image
    Image attribution tooltip

    Permission granted by Sanjeev Luther.

    Clearing hurdles in rare cancer drug development

    Rafael’s CEO, Sanjeev Luther, explains why flexibility and agility are keys to success in the rare cancer space.

    Kim Ribbink • March 14, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Liquid biopsy is a multibillion-dollar market, and InterVenn is looking to take advantage

    The company’s CEO explains how its liquid biopsy tests target a unique, untapped layer of biology.

    Taren Grom • March 14, 2022
  • story image
    Image attribution tooltip
    Permission granted by Terry Weber

    Biote CEO: Employers need to normalize women's health issues in the workforce

    A survey by Biote reveals the impact of menopause on working women.

    Robin Robinson • March 14, 2022
  • story image
    Image attribution tooltip

    Image courtesy of Ultragenyx.

    Ultragenyx's CEO on building a 'next-gen' rare disease company

    How Dr. Emil Kakkis is maintaining the soul of a startup while undergoing growth.

    Kim Ribbink • March 9, 2022
  • story image
    Image attribution tooltip

    Permission granted by Ramona Sequeira.

    Ramona Sequeira breaks PhRMA's glass ceiling

    A few weeks ago, PhRMA, the industry’s largest trade group, announced that Sequeira has officially become chair of the organization’s board of directors. She is the first woman — and first woman of color — to take on the job.

    Taren Grom • March 7, 2022
  • story image
    Image attribution tooltip

    Permission granted by Andrew Hopkins.

    Exscientia scored the largest AI deal with a Big Pharma to date — but it's just getting started

    The company’s CEO on the road ahead for AI capabilities in pharma.

    Meagan Parrish • March 4, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Candel's CEO looks to help ignite a new era of cancer treatments

    Candel Therapeutics is advancing a next-gen approach in oncology: using viruses to kill cancer cells at the site of injection.

    Taren Grom • Feb. 28, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Why plasma derived therapies have a unique edge in rare diseases

    Takeda's head of PDT R&D explains how the Japanese drug giant is advancing these emerging treatments.

    Kim Ribbink • Feb. 25, 2022
  • story image
    Image attribution tooltip
    Stock via Getty Images

    Winning buy-in from early stage biotech investors

    The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.

    Taren Grom • Feb. 11, 2022
  • story image
    Image attribution tooltip

    Permission granted by Mike Rea.

    Innovation vs. invention

    IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.

    Taren Grom • Feb. 9, 2022
  • story image
    Image attribution tooltip
    Courtesy of Saniona

    Saniona's CEO on why it takes a village to develop treatments for a rare disease

    Saniona built its village by first hiring a head of patient advocacy.

    Kim Ribbink • Feb. 8, 2022
  • story image
    Image attribution tooltip
    Retrieved from Google image.

    Gaining real-world results from a decentralized trial

    Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.

    Kelly Bilodeau • Feb. 8, 2022
  • story image
    Image attribution tooltip
    Courtesy of 23andMe

    Why 23andMe's first solo clinical trial is a big deal

    It's the first test for a compound developed with the help of the company's genetic data — and there could be plenty more to come. 

    Taren Grom • Feb. 7, 2022
  • story image
    Image attribution tooltip
    Permission granted by Mary Harmon

    PTC's vice president of patient relations outlines the importance of patient input in rare disease R&D

    You can't know what matters to rare disease patients unless you ask them.

    Kim Ribbink • Feb. 3, 2022
  • story image
    Image attribution tooltip
    Permission granted by Peter Anastasiou

    New Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality

    Read what Capsida CEO Peter Anastasiou has planned for his new role. 

    Taren Grom • Feb. 3, 2022
  • story image
    Image attribution tooltip
    Retrieved from Rare Disease.org.

    For the CEO of Travere, running a rare disease company is personal

    To kick off Rare Disease month, we interview the CEO of Travere Therapeutics

    Kim Ribbink • Feb. 1, 2022
  • story image
    Image attribution tooltip
    The image by Pixabay is licensed under CC BY 1.0

    Foghorn's CEO on why collaborations are key to unlocking precision medicine

    With a major development deal under his belt, Adrian Gottschalk is helping the company advance its innovative platform.

    Robin Robinson • Jan. 28, 2022